Scientists finally find out why statins can cause muscle pain

Statins are among the most important drugs for preventing heart disease. By lowering cholesterol, they have helped save millions of lives and reduced the chances of heart attacks and strokes. However, these benefits can come with unwanted consequences. Some patients develop muscle pain or weakness, while a small number develop serious muscle wasting that can lead to kidney failure.
Scientists at the University of British Columbia (UBC), working with colleagues at the University of Wisconsin-Madison, have identified a molecular mechanism that helps explain these problems. Their findings, published in Natural Communicationcould guide the development of safer statins that retain their cholesterol-lowering benefits while reducing muscle damage.
How Statins Start Dangerous Calcium Leakage
To investigate what happens inside muscle cells, researchers use cryo-electron microscopy, an advanced imaging technique that allows scientists to examine the structure of proteins in incredible detail. Their investigation focused on the ryanodine receptor (RyR1), a protein that regulates the movement of calcium within muscle cells.
Under normal conditions, this protein acts as a regulated gate, releasing calcium when muscles need to contract. Researchers have found that statins can interfere with this process by holding the channel open. As a result, calcium continuously escapes from areas where it should be carefully controlled, creating conditions that can damage muscle tissue.
“We were able to see, almost atom by atom, how statins enter this channel,” said lead author Dr. Steven Molinarolo, a postdoctoral researcher in the UBC department of biochemistry and molecular biology. “That calcium leakage explains why some patients experience muscle pain or, in extreme cases, life-threatening complications.”
Three Molecular Statins Reveal Mechanism Behind Muscle Damage
The researchers focused on atorvastatin, a commonly prescribed cholesterol-lowering drug. Although this drug was the focus, their results suggest that similar interactions may occur with other drugs in the statin family.
One of the most remarkable findings is the unusual way statin molecules attach to the calcium channel. Rather than working individually, the three molecules occupy a specific pocket within the protein. The first binds while the channel is closed, making it more likely to open. Two more molecules then enter the pocket and hold the channel open, allowing calcium to continue leaking.
“This is the first time we have a clear picture of how statins activate this channel,” said Dr. Filip Van Petegem, senior author and professor at UBC’s Life Sciences Institute. “It’s a big step forward because it gives us a way to design statins that don’t bind to muscle tissue.”
This detailed understanding can give drug developers a way to tackle the problem at its source. By changing certain properties of statin molecules that interfere with muscle proteins, scientists can reduce unwanted effects without interfering with the drug’s ability to control cholesterol.
A Possible Path to Safer Cholesterol Drugs
More than 200 million people worldwide use statins. Although severe muscle damage occurs in only a few patients, serious problems such as pain, weakness, and fatigue are more common. These symptoms can be so bothersome that some people stop taking their medication, potentially losing important protection against cardiovascular disease.
The discovery may eventually help researchers develop treatments that are easier to tolerate, allowing more patients to continue taking medications that reduce their risk of heart attack and stroke.
Achieving this level of understanding required very detailed photography. Working with the high-resolution macromolecular cryo-electron microscopy facility at the UBC Medical Center, the team was able to observe exactly how the statin molecules interact with the muscle protein. These structural insights link long-standing drug safety concerns to specific molecular processes, providing valuable information for future drug development.
“Statins have been a mainstay of heart care for decades,” said Dr. Van Petegem. “Our goal is to make them even safer, so that patients can benefit without fear of serious side effects.”
Although more research and drug development will be needed before these findings translate into new treatments, they provide a promising direction. For the millions of people who rely on statins to protect their hearts, future drugs with fewer muscle-related problems could make treatment more comfortable and improve the quality of daily life.
Source link

